Triple-negative (ER-/PR-/Her2-) breast cancers (TNBCs) are particularly amenable for lineage tracing studies, since they display extensive intratumor genomic heterogeneity [7] and show very high numbers of genomic mutations [7,11,15]. This evidence concerns the gene ESR1 and breast carcinoma.